SureTrader SureTrader
Home > Boards > US Listed > Biotechs > Compugen (CGEN)

6:01AM Compugen announces results showing its CGEN-15001T drug

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
surf1944 Member Profile
 
Followed By 415
Posts 22,038
Boards Moderated 2
Alias Born 09/11/06
160x600 placeholder
Compugen Appoints Senior Vice President Corporate and Business Development "PR Newswire (US)" - 12/5/2016 7:00:00 AM
Compugen to Present at 28th Annual Piper Jaffray Healthcare Conference in New York "PR Newswire (US)" - 11/21/2016 7:00:00 AM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 11/14/2016 6:10:49 AM
Compugen Immune Checkpoint Program Demonstrates Potential for Development of New Cancer Immunotherapy Treatments "PR Newswire (US)" - 11/11/2016 11:45:00 AM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 11/7/2016 7:11:46 AM
Compugen Ltd. Reports 3rd Quarter 2016 Financial Results "PR Newswire (US)" - 11/7/2016 7:07:00 AM
Compugen to Host R&D Day on December 7, 2016 in New York "PR Newswire (US)" - 11/3/2016 9:53:00 AM
Prospectus Filed Pursuant to Rule 424(b)(2) (424b2) "Edgar (US Regulatory)" - 10/14/2016 4:03:33 PM
Notice of Effectiveness (effect) "Edgar (US Regulatory)" - 10/12/2016 6:05:48 AM
Compugen Third Quarter Financial Statements to be Released November 7, 2016 "PR Newswire (US)" - 10/10/2016 7:00:00 AM
Compugen to Present at the Annual Meeting of the Society for Immunotherapy of Cancer Next Month "PR Newswire (US)" - 10/7/2016 7:00:00 AM
Compugen Discloses Development of Enhanced LINKS Platform Utilized for the Discovery of Myeloid Targets for Cancer Immunother... "PR Newswire (US)" - 8/30/2016 7:00:00 AM
Confidential Treatment Order (ct Order) "Edgar (US Regulatory)" - 8/25/2016 10:13:31 AM
Securities Registration (foreign Private Issuer) (f-3) "Edgar (US Regulatory)" - 8/9/2016 6:32:18 AM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 8/9/2016 6:12:43 AM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 8/2/2016 7:02:10 AM
Compugen Ltd. Reports 2nd Quarter 2016 Financial Results "PR Newswire (US)" - 8/2/2016 7:01:00 AM
Compugen Second Quarter 2016 Conference Call Scheduled for Tuesday, August 2, 2016 at 10:00 AM ET "PR Newswire (US)" - 7/21/2016 7:00:00 AM
Compugen Discloses Lead Therapeutic Candidate for CGEN-15029 Immuno-Oncology Program "PR Newswire (US)" - 6/22/2016 7:09:00 AM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 6/22/2016 7:02:52 AM
Compugen to Present at JMP Securities Life Sciences Conference in New York "PR Newswire (US)" - 6/15/2016 7:00:00 AM
Compugen to Present at the Jefferies Global Healthcare Conference in New York "PR Newswire (US)" - 5/23/2016 7:00:00 AM
Compugen to Present at the Oppenheimer Annual Israeli Conference in Tel Aviv "PR Newswire (US)" - 5/16/2016 7:00:00 AM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 5/10/2016 7:05:21 AM
Compugen Ltd. Reports First Quarter 2016 Financial Results "PR Newswire (US)" - 5/10/2016 7:01:00 AM
surf1944   Thursday, 02/02/12 10:57:15 AM
Re: surf1944 post# 109
Post # of 153 
6:01AM Compugen announces results showing its CGEN-15001T drug may have potential for cancer immunotherapy (CGEN) 5.30 : Co announced results demonstrating the therapeutic potential of CGEN-15001T as a drug target for treatment of multiple cancers by means of monoclonal antibody ("mAb") therapy. These results indicate that CGEN-15001T is expressed on numerous types of cancer, such as carcinomas, sarcomas, melanoma and hematological cancers as well as on immune cells. These findings, together with previous results supporting its active immunomodulatory effect, 'strongly support CGEN-15001T's potential as a powerful drug target for treatment of various solid and hematological cancers, an area of great interest to the pharmaceutical industry.'


surf's up......crikey



SureTrader
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist